Senti Bio to Host Investor Event Highlighting SENTI-202 at the 2022 ASH Annual Meeting
23. November 2022 07:55 ET
|
Senti Biosciences, Inc.
– Review of new preclinical data and clinical development plan for SENTI-202 in hematologic malignancies; also featuring KOL discussion of treatment landscape and unmet need in AML – – Live and...
Senti Bio Reports Third Quarter Financial Results and Pipeline Updates
10. November 2022 07:55 ET
|
Senti Biosciences, Inc.
- SENTI-202 on track for IND filing in 2023; clinical plans for SENTI-202 expand beyond AML to CD33and/or FLT3 expressing hematologic malignancies including MDS - - Selected development candidate for...
Senti Bio Announces New Employment Inducement Grants
28. Oktober 2022 16:05 ET
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...
Senti Bio to Participate in Chardan’s 6th Annual Genetic Medicines Conference
20. September 2022 16:02 ET
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...
Senti Bio Reports Second Quarter Financial Results and Business Updates
15. August 2022 16:05 ET
|
Senti Biosciences, Inc.
- Lead development candidate selected from SENTI-202 program; on track for IND filing in 2023 - - Expect to present CAR-NK cell therapy program data at multiple scientific conferences in 2022 - ...
Senti Bio Debuts as Publicly Traded Company Focused on Developing Next-Generation Cell and Gene Therapies Engineered with Gene Circuits
09. Juni 2022 07:30 ET
|
Senti Biosciences, Inc.
- Business combination with Dynamics Special Purpose Corp. completed today; gross proceeds from transaction to Senti Bio expected to total approximately $156.5 million - - Combined company Senti...
Senti Bio Names Dr. Kanya Rajangam to Newly Created Position of Chief Medical and Development Officer
25. Mai 2022 08:30 ET
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., May 25, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Senti Bio), a leading gene circuit company, today announced the appointment of Kanya Rajangam, MD, PhD, as...
Senti Bio Secures Additional Financing from Leaps by Bayer and Provides Update on Proposed Business Combination with Dynamics Special Purpose Corp. (DYNS)
24. Mai 2022 08:30 ET
|
Senti Biosciences, Inc.
- Leaps by Bayer led Series B investment in Senti Bio in 2021; Additional Convertible Note financing expands committed capital to PIPE investment associated with previously announced Business...
Senti Bio to Present at Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
18. April 2022 09:00 ET
|
Senti Bio
SOUTH SAN FRANCISCO, Calif., April 18, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (“Senti Bio”), a leading Gene Circuit company today announced that co-founders Tim Lu, MD, PhD, Chief...
Senti Bio to Present Preclinical Data on Cancer-Killing Allogeneic CAR-NK Cells at AACR Annual Meeting
08. März 2022 16:30 ET
|
Senti Bio
SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Senti Bio, a leading gene circuit company, today announced the acceptance of an abstract for presentation at the American Association...